Cite
HARVARD Citation
Tolaney, S. et al. (2020). Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet oncology. 21 (6), pp. 763-775. [Online].